Olema Pharmaceuticals
OLMA
200 hedge funds and large institutions have $2.27B invested in Olema Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 55 increasing their positions, 39 reducing their positions, and 12 closing their positions.
625% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 12
450% more funds holding in top 10
Funds holding in top 10: 2 → 11 (+9)
239% more capital invested
Capital invested by funds: $668M → $2.27B (+$1.6B)
76% more call options, than puts
Call options by funds: $30.8M | Put options by funds: $17.5M
59% more funds holding
Funds holding: 126 → 200 (+74)
41% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 39
32.66% more ownership
Funds ownership: 99.49% → 132.15% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$88.9M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$58.7M |
| 3 |
Janus Henderson Group
London,
|
+$55.6M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$48.9M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$46.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$34M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$20.2M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$16.8M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$16M |
| 5 |
Morgan Stanley
New York
|
-$15.8M |
OLMA Hedge Fund Activity: Q4 2025 in Review
200 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q4 2025, worth a combined $2.27B — up 239% from $668M a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new OLMA positions and 12 closed out — a net gain of 75 holders — while 55 added to existing stakes and 39 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $88.9M. The largest seller was Deep Track Capital, exiting entirely with an estimated $34M sold.
- 200 institutional investors held Olema Pharmaceuticals (OLMA) as of Q4 2025, up from 126 in Q3 2025.
- Funds reported $2.27B of Olema Pharmaceuticals stock for Q4 2025, up 239% quarter-over-quarter.
- 87 funds opened new Olema Pharmaceuticals positions in Q4 2025 and 12 closed out, a net change of +75 holders.
- The largest Olema Pharmaceuticals buyer in Q4 2025 was Fidelity Investments, an estimated $88.9M added.
- The largest Olema Pharmaceuticals seller in Q4 2025 was Deep Track Capital, an estimated $34M sold.
Based on aggregated 13F filings for Q4 2025.